Preliminary Data on the Viral Decay Accelerator KP-1461

In a pilot study involving HIV-infected patients not receiving antiretroviral therapy, KP-1461 was generally well tolerated and showed some evidence of changing the expected mutation pattern.

Most of the antiretrovirals in development represent additions to the currently available drug classes. Agents with different mechanisms of action are needed to combat broadly drug-resistant HIV and target viral reservoirs. KP-1461 belongs to a novel class of drugs — viral decay accelerators — that increase the mutation rate, with the goal of exceeding the virus's error threshold and thereby decreasing replication. In a recent manufacturer-sponsored, phase IIa study, researchers evaluated the safety, tolerability, and efficacy of 4 months of oral KP-1461 (1600 mg twice daily).

The study involved 24 HIV-infected patients who had not received antiretroviral therapy (ART) for ≥16 weeks (83% men; median age, 47.5; mean duration of HIV infection,…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Preliminary Data on the Viral Decay Accelerator KP-1461

Topics

Reviewing Author